Markets

Lantern Pharma Issued Notice Of Allowance From U.S. Patent And Trademark Office For Application Titled Method For Treating Blood Cancers

Sep 22, 2026 · 07:46 AM ET· updated 1h ago

Lantern Pharma Inc. (NASDAQ:LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and

Why It Matters

Lantern Pharma got approval to protect a new blood cancer treatment idea. This shows the company is making real progress on a new medicine.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LTRN1.42

-0.08 (-5.27%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.